ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone Lymphoma

5/6/24 6:04:38 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ADCT alert in real time by email

ADC Therapeutics SA (NYSE:ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) demonstrated a high response rate in patients with relapsed/refractory (r/r) marginal zone lymphoma (MZL).

Get the next $ADCT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ADCT

Date	Price Target	Rating	Analyst
11/8/2024	$6.00	Overweight	Stephens
5/30/2024		Overweight	Cantor Fitzgerald
3/28/2024	$11.00	Buy	Guggenheim
8/10/2023		Underweight → Neutral	JP Morgan
4/24/2023	$7.00 → $2.00	Neutral → Underperform	BofA Securities
12/6/2022	$12.00	Overweight	CapitalOne
11/9/2022	$14.00 → $7.00	Buy → Neutral	BofA Securities
9/21/2022	$5.00	Overweight	JP Morgan

More analyst ratings

$ADCT
Financials

Live finance-specific insights

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland, Nov. 7, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2024, and provided recent operational updates.
11/7/24 7:30:00 AM ET
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care
ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024
LAUSANNE, Switzerland, Oct. 31, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Thursday, November 7, 2024, at 8:30 a.m. EST to report financial results for the third quarter 2024 and provide operational updates. To access the conference call, please register here. The participant toll-free dial-in number is 1-800-836-8184 for North America and Canada. It is recommended that you join 10 minutes before the ev
10/31/24 7:15:00 AM ET
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care
ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update
ZYNLONTA® net sales of $17.0 million in 2Q 2024; Commercial profitability achieved during first half of 2024 LOTIS-7 trial enrollment on track with efficacy and safety data on eligible patients expected by year-end 2024 and mature data on all patients expected in first half of 2025 Full enrollment in LOTIS-5 trial expected before year-end 2024 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, Aug. 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the second quarter ended June 30, 2024, and provided operational updates
8/6/24 7:30:00 AM ET
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care

$ADCT
Leadership Updates

Live Leadership Updates

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and AbingworthAdditional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova PartnersFunds will be used to build out Myricx Bio's proprietary N-Myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform and advance its pipeline of NMTi-ADCs through clinical proof of concept targeting clinically validated tumour-associated antigensCompany to establish laboratory operations in London's biotech hub, and expand its management and R&D teamsMichael Bauer from Novo Holdings and Lucille Conroy from Abi
7/8/24 2:00:00 AM ET
$ADCT
$CG
Biotechnology: Pharmaceutical Preparations
Health Care
Investment Managers
Finance
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company is set to join the Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024. "We are pleased to be joining the Russell 2000® Index," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics. "This is a significant benchmark validating the focused execution of our corporate and capital allocation strategy and our progress toward multiple upcoming expected milestones throughout our hematology and solid tumor portfolios." Th
6/27/24 7:15:00 AM ET
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx'), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads based on N-Myristoyltransferase inhibition (NMTi), today announces the appointment of Dr Chris Martin as independent Chairman to its Board of Directors. Dr Martin is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the ADC space. Dr Martin was instrumental in co-founding ADC Therapeutics (NYSE:ADCT) in Jan 2012 and served as its CEO since inception until May 2022. Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York
11/15/23 3:00:00 AM ET
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care

$ADCT
Press Releases

Fastest customizable press release news feed in the world

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update
LOTIS-5 full enrollment and LOTIS-7 initial efficacy, safety update anticipated by end of 2024 Updated ZYNLONTA® Phase 2 IIT data in indolent lymphomas to be presented at the 66th American Society of Hematology Annual Meeting in December 2024 Discontinuing ADCT-601 program and prioritizing exatecan-based platform for solid tumors Company to host conference call today at 8:30 a.m. EST LAUSANNE, Switzerland, Nov. 7, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2024, and provided recent operational updates.
11/7/24 7:30:00 AM ET
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care
ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting
Oral presentation of investigator-initiated Phase 2 study evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in patients with r/r follicular lymphoma Poster presentation of first interim futility analysis of ongoing investigator-initiated Phase 2 clinical trial studying ZYNLONTA as treatment for r/r marginal zone lymphoma LAUSANNE, Switzerland, Nov. 5, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced independent, investigator-initiated study abstracts on ZYNLONTA® (loncastuximab tesirine-lpyl) have been accepted for presentation at the 66th American
11/5/24 9:47:00 AM ET
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care
ADC Therapeutics to Present at November Investor Conferences
LAUSANNE, Switzerland, Nov. 4, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in two investor conferences in November: Guggenheim Securities Healthcare Innovation Conference Date: November 11, 2024Presentation Time: 11:00 a.m. ETFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive Officer Jefferies London Healthcare Conference Date: November 19, 2024Presentation Time: 11:00 a.m. GMTFormat: Fireside ChatSpeaker: Ameet Mallik, Chief Executive
11/4/24 7:15:00 AM ET
$ADCT
Biotechnology: Pharmaceutical Preparations
Health Care

ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Chat with this insight

Recent Analyst Ratings for $ADCT

$ADCT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Stephens initiated coverage on ADC Therapeutics with a new price target

Cantor Fitzgerald initiated coverage on ADC Therapeutics

Guggenheim initiated coverage on ADC Therapeutics with a new price target

$ADCT Financials

Live finance-specific insights

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024

ADC Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update

$ADCT Leadership Updates

Live Leadership Updates

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

$ADCT Press Releases

Fastest customizable press release news feed in the world

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics to Present at November Investor Conferences

$ADCT SEC Filings

$ADCT FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

$ADCT Market Insights

Live Market Insights

$ADCT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$ADCT Large Ownership Changes

This live feed shows all institutional transactions in real time.

ADC Therapeutics SA filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 10-Q filed by ADC Therapeutics SA

ADC Therapeutics SA filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

FDA Approval for ZYNLONTA issued to ADC Therapeutics SA

Intapp, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

ADC Therapeutics Is Set To Join The Russell 2000 Index And The Broad-market Russell 3000 Index After The 2024 Russell Us Indexes Annual Reconstitution, Effective At The Open Of US Equity Markets On Monday, July 1, 2024

Cantor Fitzgerald Initiates Coverage On ADC Therapeutics with Overweight Rating

Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

Amendment: SEC Form SC 13G/A filed by ADC Therapeutics SA

$ADCT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Redmile Group, Llc bought $2,248,000 worth of shares (800,000 units at $2.81) (SEC Form 4)

Director Azelby Robert sold $20,216 worth of shares (6,995 units at $2.89), decreasing direct ownership by 12% to 53,005 units (SEC Form 4)

Director Bizzari Jean-Pierre sold $20,216 worth of shares (6,995 units at $2.89), decreasing direct ownership by 8% to 79,502 units (SEC Form 4)

Recent Analyst Ratings for
$ADCT

$ADCT
Analyst Ratings

$ADCT
Financials

$ADCT
Leadership Updates

$ADCT
Press Releases

$ADCT
SEC Filings

$ADCT
FDA approvals

$ADCT
Market Insights

$ADCT
Insider Purchases

$ADCT
Large Ownership Changes

$ADCT
Insider Trading